Showing results (341-350 of 463) with videos related to
Sort By:
Pageof 47
Nature|August 27, 2010
IkappaBbeta acts to inhibit and activate gene expression during the inflammatory responsePing Rao, Mathew S Hayden, Meixiao Long, et al.Oncotarget|November 16, 2017
Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migrationAsfar S Azmi, Yiwei Li, Irfana Muqbil, et al.Investigational New Drugs|March 17, 2007
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancersT Ciuleanu, M Diculescu, N M Hoepffner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyureaP A Philip, V L Souliotis, A L Harris, et al.Gynecologie, Obstetrique, Fertilite & Senologie|March 18, 2018
[Epidemiology and diagnosis strategy: CNGOF-HAS Endometriosis Guidelines]A Fauconnier, B Borghese, C Huchon, et al.European Journal of Cancer (Oxford, England : 1990)|February 17, 2010
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 functionAsfar S Azmi, Amro Aboukameel, Sanjeev Banerjee, et al.The Oncologist|June 6, 2018
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric AdenocarcinomaMohamed E Salem, Alberto Puccini, Joanne Xiu, et al.Cancer Chemotherapy and Pharmacology|April 13, 2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancerBassel F El-Rayes, Mark M Zalupski, Stephanie G Manza, et al.British Journal of Cancer|July 17, 1998
Phase I study of the mitomycin C analogue BMS-181174V M Macaulay, K J O'Byrne, J A Green, et al.Current Cancer Drug Targets|April 8, 2010
Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapyAsfar S Azmi, Philip A Philip, A Aboukameel, et al.Pageof 47